1 Result: Renalytix
Breaking: Renalytix's KidneyIntelX.dkd FDA-Approved, VSE Secures Up to $565M Contract
June 29th, 2023
Shares of Renalytix plc (Nasdaq: RNLX) surged over 25% in after-hours trading following the company's announcement of receiving De Novo marketing authorization from the U.S. Food and Drug Administration (FDA) for its KidneyIntelX.dkd prognostic test.. Read more
Load More Content
Want To Find Some News?
News By Industries
Recent Post
-
February 27th, 2026February 26th, 2026
Member Login